These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
903 related articles for article (PubMed ID: 28797232)
1. Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care. Heppt MV; Siepmann T; Engel J; Schubert-Fritschle G; Eckel R; Mirlach L; Kirchner T; Jung A; Gesierich A; Ruzicka T; Flaig MJ; Berking C BMC Cancer; 2017 Aug; 17(1):536. PubMed ID: 28797232 [TBL] [Abstract][Full Text] [Related]
2. The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort. Ekedahl H; Cirenajwis H; Harbst K; Carneiro A; Nielsen K; Olsson H; Lundgren L; Ingvar C; Jönsson G Br J Dermatol; 2013 Nov; 169(5):1049-55. PubMed ID: 23855428 [TBL] [Abstract][Full Text] [Related]
3. MEK inhibition may increase survival of NRAS-mutated melanoma patients treated with checkpoint blockade: Results of a retrospective multicentre analysis of 364 patients. Kirchberger MC; Ugurel S; Mangana J; Heppt MV; Eigentler TK; Berking C; Schadendorf D; Schuler G; Dummer R; Heinzerling L Eur J Cancer; 2018 Jul; 98():10-16. PubMed ID: 29843107 [TBL] [Abstract][Full Text] [Related]
4. Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma. Thomas NE; Edmiston SN; Alexander A; Groben PA; Parrish E; Kricker A; Armstrong BK; Anton-Culver H; Gruber SB; From L; Busam KJ; Hao H; Orlow I; Kanetsky PA; Luo L; Reiner AS; Paine S; Frank JS; Bramson JI; Marrett LD; Gallagher RP; Zanetti R; Rosso S; Dwyer T; Cust AE; Ollila DW; Begg CB; Berwick M; Conway K; JAMA Oncol; 2015 Jun; 1(3):359-68. PubMed ID: 26146664 [TBL] [Abstract][Full Text] [Related]
5. Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma. Carlino MS; Haydu LE; Kakavand H; Menzies AM; Hamilton AL; Yu B; Ng CC; Cooper WA; Thompson JF; Kefford RF; O'Toole SA; Scolyer RA; Long GV Br J Cancer; 2014 Jul; 111(2):292-9. PubMed ID: 24918823 [TBL] [Abstract][Full Text] [Related]
6. Prognostic and predictive values of oncogenic BRAF, NRAS, c-KIT and MITF in cutaneous and mucous melanoma. Pracht M; Mogha A; Lespagnol A; Fautrel A; Mouchet N; Le Gall F; Paumier V; Lefeuvre-Plesse C; Rioux-Leclerc N; Mosser J; Oger E; Adamski H; Galibert MD; Lesimple T J Eur Acad Dermatol Venereol; 2015 Aug; 29(8):1530-8. PubMed ID: 25623140 [TBL] [Abstract][Full Text] [Related]
7. Ponti G; Manfredini M; Greco S; Pellacani G; Depenni R; Tomasi A; Maccaferri M; Cascinu S Anticancer Res; 2017 Dec; 37(12):7043-7048. PubMed ID: 29187493 [TBL] [Abstract][Full Text] [Related]
8. Increased levels of β-catenin, LEF-1, and HPA-1 correlate with poor prognosis for acral melanoma with negative BRAF and NRAS mutation in BRAF exons 11 and 15 and NRAS exons 1 and 2. Xu S; Yang Z; Zhang J; Jiang Y; Chen Y; Li H; Liu X; Xu D; Chen Y; Yang Y; Zhang Y; Li D; Xia J DNA Cell Biol; 2015 Jan; 34(1):69-77. PubMed ID: 25343173 [TBL] [Abstract][Full Text] [Related]
9. MEK Inhibition Reverses Aberrant Signaling in Melanoma Cells through Reorganization of NRas and BRAF in Self Nanoclusters. Yakovian O; Sajman J; Arafeh R; Neve-Oz Y; Alon M; Samuels Y; Sherman E Cancer Res; 2021 Mar; 81(5):1279-1292. PubMed ID: 33355187 [TBL] [Abstract][Full Text] [Related]
10. Molecular characterization of a selected cohort of patients affected by pulmonary metastases of malignant melanoma: Hints from BRAF, NRAS and EGFR evaluation. Ulivieri A; Cardillo G; Manente L; Paone G; Mancuso AP; Vigna L; Di Stasio E; Gasbarra R; Girlando S; Leone A Oncotarget; 2015 Aug; 6(23):19868-79. PubMed ID: 26305188 [TBL] [Abstract][Full Text] [Related]
11. Correlation of somatic mutations and clinical outcome in melanoma patients treated with Carboplatin, Paclitaxel, and sorafenib. Wilson MA; Zhao F; Letrero R; D'Andrea K; Rimm DL; Kirkwood JM; Kluger HM; Lee SJ; Schuchter LM; Flaherty KT; Nathanson KL Clin Cancer Res; 2014 Jun; 20(12):3328-37. PubMed ID: 24714776 [TBL] [Abstract][Full Text] [Related]
12. Prevalence of BRAF and NRAS mutations in cutaneous melanoma patients in Taiwan. Sheen YS; Liao YH; Liau JY; Lin MH; Hsieh YC; Jee SH; Chu CY J Formos Med Assoc; 2016 Feb; 115(2):121-7. PubMed ID: 25767048 [TBL] [Abstract][Full Text] [Related]
13. BRAF mutation status is an independent prognostic factor for resected stage IIIB and IIIC melanoma: implications for melanoma staging and adjuvant therapy. Barbour AP; Tang YH; Armour N; Dutton-Regester K; Krause L; Loffler KA; Lambie D; Burmeister B; Thomas J; Smithers BM; Hayward NK Eur J Cancer; 2014 Oct; 50(15):2668-76. PubMed ID: 25070294 [TBL] [Abstract][Full Text] [Related]
14. KIT, NRAS, BRAF and PTEN mutations in a sample of Swedish patients with acral lentiginous melanoma. Zebary A; Omholt K; Vassilaki I; Höiom V; Lindén D; Viberg L; Kanter-Lewensohn L; Johansson CH; Hansson J J Dermatol Sci; 2013 Dec; 72(3):284-9. PubMed ID: 23993026 [TBL] [Abstract][Full Text] [Related]
15. Clinicopathological features and clinical outcomes associated with TP53 and BRAF Kim DW; Haydu LE; Joon AY; Bassett RL; Siroy AE; Tetzlaff MT; Routbort MJ; Amaria RN; Wargo JA; McQuade JL; Kemnade J; Hwu P; Woodman SE; Roszik J; Kim KB; Gershenwald JE; Lazar AJ; Davies MA Cancer; 2017 Apr; 123(8):1372-1381. PubMed ID: 27911979 [TBL] [Abstract][Full Text] [Related]
16. [ Spectrum of oncogene mutations is different in melanoma subtypes]. Mazurenko NN; Tsyganova IV; Lushnikova AA; Ponkratova DA; Anurova OA; Cheremushkin EA; Mikhailova IN; Demidov LV Mol Biol (Mosk); 2015; 49(6):1022-9. PubMed ID: 26710785 [TBL] [Abstract][Full Text] [Related]
17. [Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation]. Lázár V Magy Onkol; 2013 Jun; 57(2):96-9. PubMed ID: 23795354 [TBL] [Abstract][Full Text] [Related]
18. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. Long GV; Menzies AM; Nagrial AM; Haydu LE; Hamilton AL; Mann GJ; Hughes TM; Thompson JF; Scolyer RA; Kefford RF J Clin Oncol; 2011 Apr; 29(10):1239-46. PubMed ID: 21343559 [TBL] [Abstract][Full Text] [Related]
19. A real-world study of adjuvant anti-PD -1 immunotherapy on stage III melanoma with BRAF, NRAS, and KIT mutations. Sun W; Xu Y; Yan W; Wang C; Hu T; Luo Z; Zhang X; Liu X; Chen Y Cancer Med; 2023 Aug; 12(15):15945-15954. PubMed ID: 37403699 [TBL] [Abstract][Full Text] [Related]
20. Evaluation of a Rapid, Fully Automated Platform for Detection of BRAF and NRAS Mutations in Melanoma. Barel F; Guibourg B; Lambros L; Le Flahec G; Marcorelles P; Uguen A Acta Derm Venereol; 2018 Jan; 98(1):44-49. PubMed ID: 28660280 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]